CDK4 and breast cancer: These data support the strategy of combination of palbociclib with FGFR-targeting agent in this subtype of breast cancer and demonstrate the effectiveness of blocking both CDK4/6 and FGFR signaling pathways in targeting the CSC stemness involved in the drug resistance.